EZH2 functions as an inhibitor of CD4+ and CD8+ effector T-cell recruitment into the tumor microenvironment in pcALCL, favoring immune evasion, tumor progression and antitumor immunity, making it an interesting pharmacological target [304]. The gene discussed is CD8A; the disease is neoplasm.